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Background: Although high-molecular-weight (HMW) adiponectin is believed to protect against atherosclerosis,
the association between HMW adiponectin and the composition of coronary plaques is unknown. We evaluated
whether the HMW to total adiponectin ratio was associated with the presence of coronary plaque and its
composition using multi-slice computed tomography coronary angiography (MSCTCA).
Methods: Serum total and HMW adiponectin levels were measured in 53 consecutive patients (age, 71) with >50%
coronary artery stenosis detected by MSCTCA. A low-attenuation coronary plaque was defined as a plaque with a
mean CT density <50 Hounsfield units. Multivariate logistic regression analyses were performed to evaluate the
predictors of the presence of low-attenuation coronary plaques, which is thought to be high risk, on CT.
Results: Decreased serum levels of total as well as HMW adiponectin were significantly associated with the
presence of at least one calcified or non-calcified coronary artery plaque (total adiponectin level: odds ratio 0.76,
95% CI 0.58–0.99, P = 0.048; HMW adiponectin level: odds ratio 0.65, 95% CI 0.42–0.99, P = 0.047). A low ratio of
HMW to total adiponectin was significantly associated with the presence of low-attenuation coronary plaques (4.55,
1.94–21.90, P = 0.049). However, neither the total adiponectin nor the HMW adiponectin level was associated with
the presence of low-attenuation coronary plaques.
Conclusion: Lower total or HMW adiponectin levels are associated with the presence of calcified and non-calcified
coronary plaques, whereas a lower ratio of HMW to total adiponectin associated with the presence of low-
attenuation coronary plaques (thought to be high risk). Measurement of total and HMW adiponectin levels and the
HMW to total adiponectin ratio may be useful for risk stratification of coronary artery plaques.
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plaqueBackground
Atherosclerotic cardiovascular disease is the leading
cause of death worldwide [1]. Despite major advances in
the treatment of coronary heart disease patients, a large
number of victims of the disease who are apparently
healthy die suddenly without prior symptoms. Currently
available screening and diagnostic methods are insuffi-
cient to identify victims before the event occurs.* Correspondence: jsubrina@gmail.com
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reproduction in any medium, provided the orRecently, lesion composition rather than size has been
emphasized in determining the acute complications of
atherosclerotic disease in humans. Many studies have
suggested that non-obstructive lipid-rich plaques with a
thin cap are prone to rupture and result in acute coron-
ary artery occlusions [2,3] whereas obstructive, fibrous
plaques with a thick cap result in clinically stable angina
pectoris.
A large number of blood biomarkers, such as high-
sensitivity C-reactive protein (hsCRP), tumor necrosis
factor alpha, and oxidized low-density lipoprotein
(ox-LDL), involved in inflammation, oxidation, and lipidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ant role in atherogenesis [4]. Several of those biomarkers
have also been shown to be independent predictors of
cardiovascular events [5]. Recently, adiponectin, a pro-
tein secreted by adipose tissue, has been reported as an
important mediator against the development of coronary
atherosclerosis [6-8]. Serum adiponectin levels are mark-
edly decreased in patients with visceral obesity and insu-
lin resistance [9,10]. Low adiponectin levels have also
been linked with coronary artery disease (CAD) [11] and
have been shown to be a risk factor for cardiovascular
events [12]. Low adiponectin levels are also independ-
ently associated with the development of coronary artery
calcification (CAC) [13].
Adiponectin in particular is abundant in the circulation
as a low-molecular-weight trimer and a medium-
molecular-weight hexamer, but it also occurs in a high-
molecular-weight (HMW) form [14]. The HMW isoform
binds most avidly to its receptors and stimulates AMP-
activated protein kinase, which is one of the key molecules
mediating the metabolic actions of adiponectin. Recently,
several papers have reported that HMW adiponectin is
the more active form and that it has stronger anti-
atherogenic effects than other types of adiponectin
[15-18]. However, whether HMW adiponectin levels, total
adiponectin levels, or the HMW to total adiponectin ratio
is more important for vascular protection and which fac-
tor is the better predictor of the severity of coronary ath-
erosclerosis remains unclear [7,19-21].
With advances in imaging of coronary atherosclerosis,
angiographic evaluation of coronary luminal stenosis has
become a surrogate marker of the severity and extent of
atherosclerosis. However, conventional coronary angiog-
raphy has important limitations, one of which is its low
predictive value for assessing atherosclerotic plaque bur-
den and for predicting acute coronary syndrome events
[22,23]. In addition, it does not enable identification of
non-obstructive coronary plaques or determination of
the composition of atherosclerotic plaques. Recent ad-
vances in coronary imaging have opened another poten-
tial window to better understand the links between
biomarkers predictive of disease presence and complica-
tions and the anatomic diagnosis of coronary athero-
sclerosis. With advances in contrast-enhanced computed
tomography (CT) angiography, evaluation of CAC as
well as the detection and quantification of non-calcified
plaque components is now possible. To date, only two
studies have investigated the association between coron-
ary atherosclerotic plaques detected by CT angiography
and adiponectin levels [18,24]. However, their results
are inconsistent. Therefore, the purpose of this study
was to evaluate the associations between serum HMW
adiponectin levels and the HMW to total adiponectin ra-
tio and the composition of coronary artery plaquesdetected by multi-slice CT coronary angiography




Screening of study patients and indications for 64-slice
CTCA were shown in Figure 1. Patients with known or
suspected CAD were indicated for 64-slice CTCA. Pa-
tients with unstable hemodynamic situations, cardiac ar-
rhythmias (i.e., chronic atrial fibrillation or frequent
paroxysmal premature beats), inability to sustain a breath
hold for at least 5 to 10 seconds, history of allergic reac-
tion for iodinated contrast medium, high risk for contrast
nephropathy (e.g., patients with diabetes and a serum cre-
atinine concentration above 2.0 mg/dl) were contraindi-
cated for 64-slice CTCA. A total of 236 consecutive
patients with known or suspected CAD who underwent
64-slice CTCA at Toho University Ohashi Medical Center
in Japan between September 15, 2006 and January 26,
2007 were screened for eligibility for this study. Written
informed consent had been obtained from all patients. Pa-
tients with history of acute coronary syndrome (ACS, n =
31), percutaneous coronary intervention (n = 21), and/or
coronary artery bypass grafting (n = 8) were excluded, be-
cause these patients were given medications such as
statins, which may affect serum adiponectin levels. And
123 of the 176 remaining patients had normal coronary
or coronary stenosis less than 50%. Consequently, a total
of 53 patients with obstructive stable CAD were studied.
The study was approved by the ethical committee of
Toho University Ohashi Medical Center, Tokyo, Japan.
Performance of 64-slice CTCA
Patients with a resting heart rate >60 beats/min re-
ceived 1 mg/kg atenolol orally 60 min before imaging,
and all received 0.3 mg nitroglycerin sublingually
5 min before imaging. A 64-slice CT machine
(Aquilion 64; Toshiba Medical Systems, Otawara,
Japan)was used with the following parameters: colli-
mation 64 × 0.5 mm; detector pitch, 9.8–11.2; pixel
size, 0.39 mm × 0.39 mm; gantry rotation time,
350 ms; tube current, 400 mA; and voltage, 120 kV.
Contrast agent (320 mgI/ml−1; Optiray 320, Tyco
Healthcare, Tokyo, Japan) was injected at a rate of
0.06 ml/kg/s during the entire scan time as well as
for an additional 2 s, followed by administration of
0.15 ml/kg of contrast media plus 0.15 ml/kg of sa-
line solution using a dual injector. Acquisition of the
CT data and electrocardiography were started as soon
as the signal density level in the ascending aorta
reached a predefined threshold of 250 Hounsfield
units (HU). The effective radiation dose was 15–
18 mSv. Acquisition time was reduced to 200 ms by
Indications for 64-slice CTCA:
1. Follow-up for patients with known CAD
2. Patients with suspected CAD
Contraindications for 64-slice CTCA:
1. Unstable hemodynamic patients
2. Patients with arrythmia (atrial fibrillation, frequent ventricular premature 
beats)
3. Inability to sustain a breath hold for at least 5 to 10 seconds
4. History of allergic reaction for iodinated contrast medium
5. High risk for contrast nephropathy (eg, patients with diabetes and a serum 
creatinine concentration above 2.0mg/dl)
6. Judged unsuitable by a physician for any other reason.
Patients who were known or 
suspected CAD underwent 64-slice 
CTCA at Toho University Ohashi 
Medical Center in Japan between 
September15, 2006 and January 26, 
2007 (n = 236).
Patients with history of ACS (n = 31), PCI (n = 21), CABG (n = 8) were 
excluded.  
Patients were analyzed for this study  (n = 53)
Patients with coronary stenosis less than 50% were excluded (n = 123).  
Figure 1 Screening of study patients and indications for computed tomography coronary angiography. CAD; coronary artery disease,
CTCA; computed tomography coronary angiography, ACS; acute coronary syndrome, PCI; percutaneous coronary intervention, CABG; coronary
artery bypass grafting.
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gantry rotation was used for image reconstruction) in
all patients. The reconstructed CT image data were trans-
ferred to a computer workstation for post-processing
(ZIO M900; Amin/ZIO, Tokyo, Japan). Using this work-
station, both cross-sectional and curved multiplanar refor-
mation images were analyzed. These images were
interpreted by an experienced cardiologist in conjunction
with radiologists who were unaware of the patients’ de-
tailed clinical backgrounds. We defined obstructive CAD
on the CT images as stenosis >50% diameter.Assessment of coronary plaques
Plaques (calcified or non-calcified) were defined as struc-
tures >1 mm in diameter within the vessel wall adjacent to
the coronary artery lumen but distinguishable from the
perivascular tissues. A calcified coronary plaque was de-
fined as a plaque with a CT density of >300 HU. We eval-
uated images with the optimal setting for detecting non-
calcified coronary plaques and outer vessel boundaries.
The setting was on average obtained at a width
representing 155% of the mean intensity within the lumen
and at a level representing 65% of the mean intensity, as
reported previously [25]. A non-calcified coronary plaque
was defined as a plaque with a CT density of ≤130 HU. A
low-attenuation coronary plaque was defined as a plaque
with a mean CT density of <50 HU within a non-calcified
coronary plaque. A plaque with a mean CT density of <50HU is considered a lipid-rich plaque (soft plaque) in IVUS
imaging [26].Blood test
Blood samples were taken from all patients for lipid ana-
lysis when 64-slice CTCA was performed, and levels of
fasting glucose, fasting insulin, low density lipoprotein-
cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), triglyceride, HbA1c, and high-sensitivity C-
reactive protein (hsCRP) were measured. Blood glucose
and insulin levels were determined by glucose dehy-
drogenase method and chemiluminescent immunoassay,
respectively. Serum levels of LDL-C, HDL-C, and trigly-
ceride were determined by enzymatic colorimetric
method. HbA1c levels were determined by latex
agglutination-turbidimetric immunoassay, and serum
hsCRP levels were determined by latex nepherometric
method. The homeostasis model assessment index of
insulin resistance (HOMA-IR) value was calculated as
fasting glucose level (mg/dL) × fasting insulin level
(μU/ml)/405. Total and HMW adiponectin were
measured by an enzymed-linked immunosorbent assay
(ELISA) method using a kit from Daiichi-kagakuyakuhin
Co. (Tokyo, Japan). In brief, adiponectin circulates in
plasma in 3 forms: trimer, hexamer, and in a HMW form:
the HMW form consists of 12–18 subunits. Pretreatment
with protease II was used to breakdown the trimers and
hexamers, and the remaining HMW subunits were
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measured by ELISA.
Statistical analysis
Descriptive characteristics for all variables are expressed
as mean±SD for normally distributed continuous variables,
medians with an interquartile range for non-normally
distributed continuous variables, and percentages for cat-
egorical variables. Differences in characteristics between
subjects with and without plaques (calcified and non-
calcified) or between subjects with or without coronary
low attenuation plaques were assessed using a chi-square
test for categorical variables, a Mann–Whitney test, and a
t-test as appropriate for non-normal and continuous
variables. Univariate and multivariate logistic regression





Diabetes mellitus (%) 40
Hypertension (%) 78
Glucose (mg/dL) 110.0 (100.0-176.0)
LDL-Cholesterol (mg/dL) 88.5 (84.0-137.0)
HDL-Cholesterol (mg/dL) 59.0 (46.0-64.0)
Triglyceride (mg/dL) 114.5 (88.0-192.0)
HbA1c (mg/dL) 5.3 (4.9-6.5)
HOMA-IR 2.0 (1.5-8.8)






Diabetes mellitus (%) 44
Hypertension (%) 91
Glucose (mg/dL) 108.0 (100.0-139.0)
LDL-Cholesterol (mg/dL) 110.0 (99.0-132.0)
HDL-Cholesterol (mg/dL) 106.0 (85.0-127.0)
Triglyceride (mg/dL) 126.0 (94.0-222.0)
HbA1c (mg/dL) 5.5 (5.2-6.2)
HOMA-IR 2.4 (1.2-7.9)
hsCRP (mg/dL) 0.04 (0.03-0.10)
BMI (kg/m2) 23.06±2.5
LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1c, hemoglobin A1c
high-sensitivity C-reactive protein; BMI, body mass index.coronary plaques and total adiponectin levels, HMW
adiponectin levels, and the HMW to total adiponectin
ratio. Receiver-operating characteristic (ROC) analyses
were performed to quantify the power of the total
adiponectin level, HMW adiponectin level, and HMW
to total adiponectin ratio for predicting the presence of
coronary artery plaques. Optimal cut-off values for each
of these factors were determined to provide the highest
diagnostic accuracy for predicting the presence of calci-
fied and non-calcified coronary plaques. In addition, to
better understand the roles of adiponectin, HMW
adiponectin, and the HMW to total adiponectin ratio in
predicting the presence of low-attenuation coronary
plaques, logistic regression was performed using the opti-
mal cut-off values for all adipokines. Three models were





























; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP,
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third model was additionally adjusted for HDL choles-
terol. Two-sided P values of <0.05 were considered sta-
tistically significant. All statistical analyses were
performed using STATA version 12.0 (Lakeway Drive,
College Station, Texas USA).
Results
Coronary plaques and adiponectin levels
The clinical characteristics of the study subjects classi-
fied according to the presence and absence of plaques
(calcified and non-calcified) or presence and absence of
coronary low attenuation-plaques are shown in Table 1.
No significant differences were observed between groups
in sex, age, conventional coronary risk factors such as
smoking, hypertension, and diabetes mellitus. Moreover,
no significant differences were observed in serum LDL
cholesterol, triglyceride, hemoglobin A1c levels, the
HOMA-IR score, hsCRP, and body mass index (BMI).
High-density lipoprotein (HDL) cholesterol levels were
significantly lower in subjects with plaques compared
with those without plaques (P = 0.02). No significant as-
sociations were observed for any of the covariatesFigure 2 Box plots showing differences in the total adiponectin level
total adiponectin ratio in patients with and without coronary artery pbetween coronary with and without low attenuation-
plaque.
Figure 2 shows total adiponectin levels, HMW adiponectin
levels, and the HMW to total adiponectin ratio in subjects
with and without coronary plaques (calcified and non-
calcified). No significant difference was observed between
subjects with and without coronary plaques in terms of
plasma total adiponectin levels, HMW adiponectin levels,
or the HMW to total adiponectin ratio. However, there
was a trend toward lower total adiponectin levels in sub-
jects with coronary plaques.
Figure 3 shows the ROC curves for plasma total
adiponectin levels, HMW adiponectin levels, and the
HMW to total adiponectin ratio and predictive values
for the presence of coronary artery plaques. The area
under the curve (AUC) for total adiponectin levels
(0.636), HMW adiponectin levels (0.645), and the HMW
to total adiponectin ratio (0.653) was similar.
Table 2 shows the association of total adiponectin,
HMW adiponectin, HMW to total adiponectin ratio with
coronary plaques. In unadjusted model decreased total
adiponectin and HMW adiponectin levels were signifi-
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1-Specificity
Total adiponectin ROC area: 0.636
HMW adiponectin ROC area: 0.645
HMW:Total adiponectin ROC area: 0.654
Figure 3 Receiver-operating characteristic curves of plasma levels of total adiponectin, high-molecular-weight (HMW) adiponectin, and
the HMW to total adiponectin ratio and predictive values for the presence of coronary artery plaques.
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significant. Further adjustment for HDL cholesterol did
not change the association. The fully adjusted odds ratios
of total adiponectin levels (per 1.0 μg/ml) and HMW
adiponectin levels (per 1.0 μg/ml) for the presence of cor-
onary plaques were 0.76 (0.58–0.99) and 0.65 (0.42–0.99),
respectively.
Predictors of low-attenuation coronary plaque
In our second series of analyses, we compared serum total
adiponectin levels, HMW adiponectin levels, and the
HMW to total adiponectin ratio between subjects with
and without low-attenuation coronary plaques. Figure 4Table 2 Predictors for the presence of plaque
Predictors Odds ratio 95% CI P valuea
Total adiponectin (μg/mL)
Unadjusted 0.76 0.59-0.98 0.036
Age- and sex-adjusted 0.75 0.57-0.99 0.041
Multivariable-adjustedb 0.76 0.58-0.99 0.048
HMW adiponectin (μg/mL)
Unadjusted 0.64 0.43-0.97 0.036
Age- and sex-adjusted 0.63 0.41-0.97 0.036
Multivariable-adjustedb 0.65 0.42-0.99 0.047
HMW/Total adiponectin
Unadjusted 0.95 0.89-1.01 0.11
Age- and sex-adjusted 0.95 0.89-1.01 0.14
Multivariable-adjustedb 0.95 0.89-1.02 0.16
HMW adiponectin, high molecular weight adiponectin; CI, confidence interval.
aBased on logistic regression analysis.
bAdditionally adjusted for HDL cholesterol.shows total adiponectin levels, HMW adiponectin levels,
and the HMW to total adiponectin ratio in subjects with
and without low-attenuation coronary plaques. No signifi-
cant differences were observed in plasma total and HMW
adiponectin levels between subjects with and without low-
attenuation coronary plaques. However, a significant dif-
ference was observed in the HMW to total adiponectin ra-
tio between subjects with and without low-attenuation
coronary plaques (median 44% and 33%, respectively, P =
0.05).
Figure 5 shows the ROC curves of plasma total
adiponectin levels, HMW adiponectin levels, and the
HMW to total adiponectin ratio for predicting the pres-
ence of low-attenuation coronary plaques. AUC for the
HMW to total adiponectin ratio was larger (0.636) than
that for total and HMW adiponectin levels (0.50 and
0.60, respectively). The optimal cut-off values for total
adiponectin levels, HMW adiponectin levels, and the
HMW to total adiponectin ratio for the presence of low-
attenuation coronary plaques were 4.3 μg/ml, 1.8 μg/ml,
and 43.8%, respectively.
Table 3 shows the association of total adiponectin,
HMW adiponectin, and HMW to total adiponectin ratio
with coronary low-attenuation plaque. Multivariate logis-
tic regression showed that the HMW to total adiponectin
ratio, but not total or HMW adiponectin levels, was sig-
nificantly associated with the presence of low-attenuation
coronary plaques. In age- and sex-adjusted model subjects
with a HMW to total adiponectin ratio of <43.8% had a
higher risk (3.87 times) of having a low-attenuation coron-
ary plaque than those with a higher ratio (P = 0.046). Fur-
ther adjustment for HDL cholesterol did not change the
Figure 4 Box plots showing differences in total adiponectin levels, high-molecular-weight (HMW) adiponectin levels, and the HMW to
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1-Specificity
Total adiponectin ROC area: 0.503
HMW adiponectin ROC area: 0.600
HMW:total adiponectin ROC area: 0.673
Figure 5 Receiver-operating characteristic curves of plasma levels of total adiponectin, high-molecular-weight (HMW) adiponectin, and
the HMW to total adiponectin ratio and predictive values for the presence of low-attenuation coronary plaques.
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Table 3 Predictors for the presence of low attenuation
plaque
Predictors Odds ratio 95% CI P valuea
Total adiponectin <4.3 μg/mL
Unadjusted 1.06 0.29-3.86 0.93
Age and sex adjusted 1.03 0.26-4.12 0.96
Multivariable-adjustedb 0.94 0.23-3.82 0.94
HMW adiponectin <1.8 μg/mL
Unadjusted 2.79 0.80-9.8 0.107
Age and sex adjusted 2.42 0.65-9.01 0.19
Multivariable-adjustedb 2.94 0.75-11.52 0.12
HMW/Total adiponectin <43.8%
Unadjusted 5.42 1.25-23.49 0.024
Age and sex adjusted 3.87 1.82-18.14 0.046
Multivariable-adjustedb 4.55 1.94-21.90 0.049
HMW adiponectin, high molecular weight adiponectin; CI, confidence interval.
a Based on logistic regression analysis.
b Additionally adjusted for HDL cholesterol.
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and HMW adiponectin levels of <1.8 μg/ml were not asso-
ciated with the presence of low-attenuation coronary
plaques.Discussion
Our study was designed to investigate associations be-
tween levels of various forms of circulatory adiponectin
and the presence of calcified and non-calcified coronary
plaques in subjects with obstructive stable CAD. We
also extended our analysis to include the presence of
low-attenuation coronary plaques. We found that (1) cir-
culatory total adiponectin and HMW adiponectin levels
were significantly and inversely associated with the pres-
ence of calcified and non-calcified coronary plaques and
(2) the HMW to total adiponectin ratio was significantly
and inversely associated with the presence of low-
attenuation coronary plaques in subjects with obstruct-
ive stable CAD. No significant association was observed
between the HMW to total adiponectin ratio and the
presence of calcified and non-calcified coronary plaques.
Circulatory levels of HMW and total adiponectin are im-
portant predictors of the presence of calcified and non-
calcified coronary plaques, whereas the HMW to total
adiponectin ratio is important for predicting the pres-
ence of low-attenuation coronary plaques. Furthermore,
in the present study subjects with obstructive stable
CAD, none of the traditional demographic or clinical pa-
rameters, except for plasma HDL levels, was useful for
predicting the presence of calcified and non-calcified
coronary plaques or low-attenuation coronary plaques.
In our study, lower plasma HDL levels were signifi-
cantly associated with the presence of calcified and non-calcified coronary plaques. In a prospective observational
cohort study, only diabetes and the HDL level, but not
other factors such as hypertension, hypercholesterolemia,
hypertriglyceridemia, and hyper-LDL cholesterolemia,
were associated with the presence of angiographically ob-
structive CAD [27]. Another study investigating a signifi-
cant association between the HDL level and CAC
demonstrated that BMI, fasting glucose levels, fasting tri-
glyceride levels, HDL cholesterol levels, and blood pres-
sure clustered together under a single latent factor, and
that this latent factor was associated with CAC [28].
Therefore, even if other clinical parameters were not sig-
nificantly associated with the presence of coronary artery
plaques, the HDL level could be an important background
characteristic for the development of coronary plaques in
subjects with obstructive stable CAD.
In a previous study, low circulatory levels of adiponectin
were found to be an independent predictor of the pres-
ence of calcified and non-calcified coronary atheroscler-
otic plaques [24]. Another study [29] showed that higher
plasma adiponectin levels were associated with a lower
risk of ACS, suggesting that the pathophysiological role of
adiponectin may be related to the stability of atheroscler-
otic plaque. Consistent with these studies, we found
by multivariable logistic regression that a higher total
adiponectin level was associated with a lower risk of the
presence of coronary atherosclerotic plaque. On the other
hand, another study showed no significant association be-
tween total adiponectin levels and coronary artery plaques
[18]. Differences in the characteristics of the study sub-
jects and in sample size might explain this discrepancy. In
addition, we found a similar association between HMW
adiponectin levels and the presence of coronary plaques in
our study subjects. In a recent study, HMW adiponectin
has been suggested to be a better predictor of coronary
artery plaque characteristics and the progression of ath-
erosclerosis than total adiponectin levels [18]. Previous
studies have indicated that HMW adiponectin is associ-
ated with the extent of CAD [30] and increased arterial
stiffness [16] and concluded that HMW adiponectin
might have higher biological activity than other types of
adiponectin. In our study HMW and total adiponectin
might have a similar power for predicting the presence
of coronary artery plaques in subjects with obstructive
stable CAD.
In our study, although total and HMW adiponectin
levels were not associated with the presence of low-
attenuation coronary plaques, a lower ratio of HMW to
total adiponectin was associated with the presence of
coronary low-attenuation plaques. In a previous study,
both HMW adiponectin levels and the HMW to total
adiponectin ratio were found to be inversely correlated
with the extent of CAD [30]. Another study showed that
a lower ratio of HMW to total adiponectin was
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ever, von Eynatten et al. reported that neither the total
adiponectin nor the HMW adiponectin level was an inde-
pendent predictor for cardiovascular events in patients
with CAD [21]. Thus, there is currently no consistent evi-
dence for determining whether total adiponectin levels,
HMW adiponectin levels, or the HMW to total adiponectin
ratio is a more reliable marker for predicting CAD severity.
The inverse association of HMW to total adiponectin ratio
with the presence of coronary low-attenuation plaques sup-
ports the findings of Liang et al. who demonstrated that a
lower ratio of HMW to total adiponectin was associated
with the severity of angiographic coronary atherosclerosis
[31]. Our ROC analysis also demonstrated that the predict-
ive power of the HMW to total adiponectin ratio tended to
be higher than that of the total and HMW adiponectin level
for predicting the presence of low-attenuation coronary
plaques.
Our study has several limitations. First, the sample size
was relatively small. Second, the effects of potential
confounding factors such as hsCRP, insulin resistance,
and other adipokines have not been completely evalu-
ated in terms of the association between adiponectin
and coronary artery plaques. Third, diabetic subjects re-
ceiving Pioglitazone may bias our results due to possible
effects of medication on adiponectin levels and coronary
artery plaques. However, the number of patients taking
Pioglitazone was very few in our study subjects (4 sub-
jects are taking Pioglitazone out of 24 diabetic patients),
so their impact on results was very low. Finally, our
study subjects were not a random sample of invasive
coronary angiography-based CAD patients, but a con-
secutive sample of patients with CT-based obstructive
stable CAD. Caution is required when generalizing the
present results to suspected cases of CAD as well as to
patients with ACS.
Conclusion
In conclusion, in our patients with obstructive stable CAD,
lower plasma levels of total and HMW adiponectin were
associated with the presence of calcified and non-calcified
coronary artery plaques. On the other hand, a lower ratio
of HMW to total adiponectin was associated with the pres-
ence of low-attenuation coronary plaques. Therefore, total
and HMW adiponectin levels are important markers for
predicting the presence of coronary artery plaques, and the
HMW to total adiponectin ratio is important for predicting
the presence of low-attenuation coronary plaques. Further
large-scale, prospective clinical studies are warranted to
elucidate the underlying mechanism.
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